"Tegafur" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Congener of FLUOROURACIL with comparable antineoplastic action. It has been suggested especially for the treatment of breast neoplasms.
| Descriptor ID |
D005641
|
| MeSH Number(s) |
D03.383.742.698.875.404.850
|
| Concept/Terms |
Tegafur- Tegafur
- 1-(Tetrahydro-2-furanyl)-5-fluorouracil
- N1-(2'-Tetrahydrofuryl)-5-fluorouracil
- 1-(2-Tetrahydrofuryl)-5-fluorouracil
- 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione
|
Below are MeSH descriptors whose meaning is more general than "Tegafur".
Below are MeSH descriptors whose meaning is more specific than "Tegafur".
This graph shows the total number of publications written about "Tegafur" by people in this website by year, and whether "Tegafur" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 2004 | 0 | 1 | 1 |
| 2006 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tegafur" by people in Profiles.
-
Grau JJ, Caballero M, Monzó M, Muñoz-García C, Domingo-Domenech J, Navarro A, Conill C, Campayo M, Bombí JA. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol. 2008 Aug 01; 98(2):130-4.
-
Lembersky BC, Wieand HS, Petrelli NJ, O'Connell MJ, Colangelo LH, Smith RE, Seay TE, Giguere JK, Marshall ME, Jacobs AD, Colman LK, Soran A, Yothers G, Wolmark N. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol. 2006 May 01; 24(13):2059-64.
-
Grau JJ, Domingo-Domenech J, Morente V, Pera M, Garcia-Valdecasas JC, Fuster J, Bombí A, Mellado B, Albanell J, Gascón P. Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology. 2004; 66(3):226-33.
-
Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M, Creaven PJ. A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol. 1996; 37(6):581-6.
-
Creaven PJ, Rustum YM, Petrelli NJ, Gorbunova VA. Clinical studies of the modulation of Ftorafur. Adv Exp Med Biol. 1993; 339:253-62; discussion 263.